|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02607 SH PHARMA
Nominal 
13.000 +0.240 (+1.881%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 260,295,089 | 12.205% | 231,981,300 | 215,824,259 | 191,909,156 | 186,565,796 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (436,505) | 2.660% | (425,194) | (345,767) | (742,161) | (1,182,031) | |
| Profit / (Loss) on Disposal | 92,475 | -93.573% | 1,438,918 | 58,289 | 52,149 | 71,336 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 129,329 | -75.447% | 526,743 | 789,596 | 1,009,547 | 765,186 | |
| Profit / (Loss) before Taxation | 7,054,297 | -19.914% | 8,808,353 | 8,143,815 | 7,175,483 | 6,262,467 | |
| Taxation | (1,887,726) | 3.930% | (1,816,339) | (1,869,245) | (1,570,219) | (1,431,725) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (1,398,571) | 1.724% | (1,374,863) | (1,181,102) | (1,109,047) | (749,748) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,768,000 | -32.920% | 5,617,152 | 5,093,467 | 4,496,217 | 4,080,994 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,485,758 | 13.141% | 1,313,192 | 1,245,369 | 1,239,584 | 1,258,772 |
| Depreciation & Amortisation | 2,379,459 | -1.579% | 2,417,627 | 2,326,697 | 2,298,453 | 2,019,827 |
| Directors' Emoluments | 18,467 | -10.333% | 20,595 | 19,753 | 18,111 | 19,484 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 102.000 | -36.646% | 161.000 | 179.000 | 158.000 | 144.000 |
| DPS (cts) | 41.000 | -- | 61.000 | 42.000 | 48.000 | 44.000 |
| Dividend Payout Ratio (%) | 40.196% | -- | 37.888% | 23.464% | 30.380% | 30.556% |
| Cash flow per share ($) | 1.413 | -- | 1.362 | 1.781 | 2.408 | 2.119 |
| NBV per share ($) | 18.504 | -- | 18.137 | 17.367 | 15.958 | 14.658 |
| Remarks: | Real time quote last updated: 29/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,941,911 |
| %Change | 12.725% |
| EPS / (LPS) | RMB 0.790 |
| NBV Per Share (¥) | RMB 18.898 |